Navigation Links
New target for anti-flu drug development
Date:8/15/2007

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.

Their findings have been published in the August 15, 2007 issue of the journal Cell Cycle.

The potential drug target is the flu protein M2, long known to be highly conserved between avian and human strains of the virus. Scientists at Cure Lab found that this M2 protein may single-handedly kill human cells.

This effect may constitute a previously unknown mechanism of influenza virus pathogenicity said Dr. Alex Shneider, senior author on the paper and CEO of the company. If so, drugs that are shown to prevent M2-dependent cell killing have the potential to be used for the treatment of flu.

Membranes covering human and avian cells do not allow ions to move in and out of the cell freely, thus maintaining internal homeostasis. M2 protein of flu virus forms ion channels allowing ion trafficking into cells that cells no longer control. Dr. Shneider and his group not only demonstrated that M2 kills mammalian cells, but also showed that ion channeling through M2 pores may be a molecular mechanism of this cell killing process. Dr. Shneider said that Developing drugs which block M2 ion channels could reduce or eliminate M2-induced cell death, and thus may be a new strategy for targeted development of anti-influenza drugs.

In collaboration with Dr. Vladimir L. Gabai from Boston University, and Dr. Shamil R. Sunyaev from Harvard Medical School scientist from Cure Lab, Inc. have developed mutant forms of M2 protein, where the ion channel is blocked. The researchers have shown that these specific mutations they introduced in the protein significantly reduces its ability to kill the cell. From the point of view of the pharmaceutical industry and feasibility studies, introducing mutations into a protein, which mimic an effect of a future drug, is a way to validate the feasibility of a drug target.

Dr. Shneider said that an M2-targeted search for new anti-influenza drugs could lead to a new generation of medicines which will complement those currently used for influenza disease prevention and treatment. Dr. Petr Ilyinskii, a principal scientist at Cure Lab and the first author on the paper also pointed out that This is especially important since an increasing number of influenza strains are becoming resistant to the drugs that are now widely used.


'/>"/>

Contact: Alex Shneider
thoidis@curelab.com
609-841-1201
Cure Lab, Inc.
Source:Eurekalert

Related biology news :

1. New binding target for oncogenic viral protein
2. Ancient olfaction protein is shared by many bugs, offering new pest control target
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. A bacterial genome reveals new targets to combat infectious disease
5. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
6. Researchers identify target for cancer drugs
7. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
8. Potential Drug Target For Treating Cocaine Abuse Found
9. Study reveals candidate targets for anti-retroviral therapeutics
10. MUHC researchers make cancer target breakthrough
11. Future diabetes drugs may target new protein interaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... Muncie, IN (PRWEB) , ... April 21, 2017 , ... ... year to 11 high school graduates from across the nation. The scholarships are created ... of AMA member dues. , Scholarship criteria are set by the AMA Scholarship Committee, ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq Technology ... announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed to ... global industry association connecting the electronics manufacturing supply chain. The mission of the ...
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention ... and clinical research aimed at treating diseases and medical conditions. ... Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ... access our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
Breaking Biology Technology: